Your browser is no longer supported. Please, upgrade your browser.
CGEN Compugen Ltd. monthly Stock Chart
CGEN [NASD]
Compugen Ltd.
Index- P/E- EPS (ttm)-0.37 Insider Own12.00% Shs Outstand83.17M Perf Week0.70%
Market Cap1.05B Forward P/E- EPS next Y-0.47 Insider Trans0.00% Shs Float82.38M Perf Month-2.84%
Income-27.60M PEG- EPS next Q-0.10 Inst Own53.30% Short Float4.49% Perf Quarter-22.94%
Sales- P/S- EPS this Y-5.10% Inst Trans10.34% Short Ratio2.83 Perf Half Y-15.14%
Book/sh1.53 P/B8.50 EPS next Y-27.00% ROA-23.30% Target Price20.38 Perf Year114.52%
Cash/sh- P/C- EPS next 5Y- ROE-27.00% 52W Range5.20 - 19.90 Perf YTD118.12%
Dividend- P/FCF- EPS past 5Y-13.10% ROI- 52W High-34.67% Beta2.64
Dividend %- Quick Ratio16.90 Sales past 5Y- Gross Margin- 52W Low150.00% ATR0.78
Employees61 Current Ratio16.90 Sales Q/Q- Oper. Margin- RSI (14)44.66 Volatility6.62% 5.77%
OptionableYes Debt/Eq0.00 EPS Q/Q6.00% Profit Margin- Rel Volume0.45 Prev Close12.33
ShortableYes LT Debt/Eq0.00 EarningsNov 05 BMO Payout- Avg Volume1.31M Price13.00
Recom1.40 SMA20-1.00% SMA50-12.77% SMA200-5.81% Volume587,692 Change5.43%
May-26-20Resumed JMP Securities Mkt Outperform $18
May-13-20Initiated Stifel Buy $19
May-07-20Initiated SVB Leerink Outperform
Apr-22-20Initiated ROTH Capital Buy $28
Mar-24-20Initiated SunTrust Buy $16
Jan-16-20Initiated Cantor Fitzgerald Overweight $10
Mar-29-18Initiated Oppenheimer Outperform
Feb-01-16Resumed Oppenheimer Outperform
Oct-15-15Initiated FBR Capital Outperform $14
Apr-23-15Resumed Jefferies Buy $11
Apr-21-15Initiated Oppenheimer Outperform $11
Feb-07-14Initiated MLV & Co Buy $14
Dec-28-09Reiterated Cantor Fitzgerald Buy $5 → $12
Jul-29-09Initiated Cantor Fitzgerald Buy $6.50
Nov-11-20 06:09AM  
Nov-10-20 07:00AM  
Nov-05-20 10:01PM  
07:00AM  
Nov-03-20 12:19PM  
Nov-02-20 07:00AM  
Oct-28-20 12:55PM  
Oct-27-20 07:00AM  
Oct-26-20 08:45AM  
Oct-22-20 07:00AM  
Sep-30-20 07:15AM  
Sep-12-20 10:59AM  
Sep-09-20 01:35AM  
Sep-08-20 07:00AM  
Sep-03-20 07:00AM  
Aug-28-20 07:00AM  
Jul-31-20 02:31AM  
Jul-30-20 07:00AM  
Jul-16-20 07:00AM  
Jul-14-20 03:35PM  
Jun-22-20 02:40PM  
Jun-01-20 07:00AM  
May-27-20 07:00AM  
May-20-20 07:02AM  
May-18-20 08:46AM  
May-13-20 09:48AM  
May-08-20 02:39PM  
10:52AM  
May-06-20 10:00PM  
07:00AM  
May-04-20 11:57AM  
Apr-30-20 12:00PM  
12:00PM  
12:00PM  
Apr-27-20 06:05AM  
06:00AM  
Apr-24-20 10:50AM  
Apr-23-20 07:00AM  
Apr-22-20 08:22AM  
Apr-20-20 07:00AM  
Apr-14-20 07:00AM  
Apr-06-20 07:00AM  
Mar-17-20 07:00AM  
Mar-12-20 06:05AM  
Mar-11-20 04:01PM  
Mar-10-20 10:00AM  
Mar-09-20 07:10AM  
Feb-20-20 07:05AM  
07:00AM  
Feb-10-20 07:58AM  
07:00AM  
Feb-07-20 07:00AM  
Feb-04-20 07:00AM  
Jan-29-20 08:30AM  
Jan-16-20 07:47PM  
Jan-09-20 07:00AM  
Jan-08-20 07:00AM  
Dec-23-19 08:04PM  
Dec-20-19 07:00AM  
Dec-17-19 09:11AM  
Dec-12-19 11:56AM  
11:35AM  
Dec-11-19 09:04AM  
05:31AM  
Dec-03-19 12:00PM  
Nov-11-19 07:00AM  
Nov-06-19 08:30AM  
Nov-05-19 08:06AM  
08:05AM  
Nov-04-19 07:00AM  
Oct-28-19 07:00AM  
Oct-12-19 09:28AM  
Oct-10-19 09:00AM  
Oct-02-19 07:00AM  
Sep-19-19 07:00AM  
Aug-28-19 12:52PM  
Aug-22-19 12:01PM  
Aug-14-19 12:18PM  
Aug-13-19 11:53AM  
Aug-08-19 11:20AM  
Aug-05-19 04:16PM  
07:00AM  
Jul-22-19 07:00AM  
Jul-16-19 07:00AM  
Jul-02-19 07:00AM  
Jun-27-19 03:07PM  
03:05PM  
Jun-26-19 09:00AM  
Jun-12-19 09:14AM  
Jun-03-19 07:00AM  
May-23-19 09:00AM  
May-22-19 07:00AM  
May-20-19 06:08PM  
04:00PM  
10:13AM  
07:05AM  
07:00AM  
May-06-19 07:00AM  
Apr-18-19 09:00AM  
Apr-03-19 07:00AM  
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.